Voriconazole is a classical antifungal drug that is often used to treat CNS fungal infections due to its permeability through the BBB.
EvolvePK+ Comparison Flyer
Only one platform can integrate GastroPlus PBPK outcomes during early design and lead optimization.
Design and Evaluation of 3-Phenyloxetane Derivative Agonists of the Glucagon-Like Peptide-1 Receptor
Various small molecule GLP1R agonists have been developed and tested for treating type 2 diabetes (T2DM) and obesity.
3 Clinical Quality Problems That Simulation Training Solves
Want to see fewer protocol deviations and agile change management in your clinical trials while also reducing burdens on research site staff?
Targeting Complement to Reduce Disease Activity: Challenges and Opportunities in the Publicly Available Data (Part Two)
In part one of this complement blog series, the complement cascade and its role in various diseases was introduced, as well as the potential for mechanistic modeling to support development of complement‑targeted therapeutics. COMPLEMENTsym, a quantitative systems pharmacology (QSP) model of complement focused on the alternative and terminal pathways (AP, TP, respectively) was introduced.
Comparison of drug-induced liver injury risk between propylthiouracil and methimazole: A quantitative systems toxicology approach
Propylthiouracil (PTU) and methimazole (MMI), two classical antithyroid agents possess risk of drug-induced liver injury (DILI) with unknown mechanism of action.
Redefining Statin Dosage Post-Gastric Bypass: Insights from a Population Pharmacokinetics–Pharmacodynamics Link Approach
Roux-en-Y gastric bypass (RYGB) involves creating a small stomach pouch, bypassing part of the small intestine, and rerouting the digestive tract.
Scaling approaches for the prediction of human clearance of LNA-i-mir-221: A retrospective validation
LNA-i-miR-221 is a novel microRNA(miRNA)-221 inhibitor designed for the treatment of human malignancies.
Simulations Plus Releases DILIsym® X
Updated quantitative systems toxicology (QST) software investigates and predicts drug-induced liver injury (DILI)
Don’t Wait Until Phase III: Why Early DILI Prediction is Key to Drug Development Success
As anyone who has worked in the pharmaceutical industry for awhile can tell you, there are many challenges, but one in particular keeps many of us up at night – the specter of drug-induced liver injury (DILI) lurking later in the drug development process.
Simulations Plus Releases ADMET Predictor® Version 12
Enhancements in key models power HT-PBPK simulations and AI-driven drug design with unprecedented performance and accuracy.
ADMET Predictor®12: Predict with Confidence
Stay ahead of the competition with ADMET Predictor® 12!
ADMET Predictor® 12 Product Brochure
Proven algorithms. Premium data. Predictions you can rely on.
Computational approach for drug discovery against Gardnerella vaginalis in quest for safer and effective treatments for bacterial vaginosis
Bacterial vaginosis (BV), primarily attributed to Gardnerella vaginalis, poses significant challenges due to antibiotic resistance and suboptimal treatment outcomes.
Development and Application of a Physiologically Based Pharmacokinetic Model for Elagolix in the Adult and Adolescent Population
Endometriosis, a common and distressing gynecological condition, affects fertility and causes pain, is often managed with medications such as Elagolix.
Oral Absorption from Surfactant-Based Drug Formulations: The Impact of Molecularly Dissolved Drug on Bioavailability
Enabling drug formulations are often required to ensure sufficient absorption after oral administration of poorly soluble drugs.
Simulations Plus to Participate in KeyBanc’s 25th Annual Technology Leadership Forum
Simulations Plus to Participate in KeyBanc’s 25th Annual Technology Leadership Forum
Cellulose ether and carbopol 971 based gastroretentive controlled release formulation design, optimization and physiologically based pharmacokinetic modeling of ondansetron hydrochloride minitablets
This study aims to design and optimize ondansetron (OND) gastro-retentive floating minitablets for better and prolonged control of postoperative nausea and vomiting (PONV) with improved patient compliance.
The Power of Simulation Training
Experience in Clinical Trial Training
Establishing Virtual Bioequivalence and Clinically Relevant Specifications for Omeprazole Enteric-Coated Capsules by Incorporating Dissolution Data in PBPK Modeling
Currently, Biopharmaceutics Classification System (BCS) classes I and III are the only biological exemptions of immediate-release solid oral dosage forms eligible for regulatory approval.